The standard first-line treatment for advanced NSCLC without actionable oncogenic drivers and with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) < 50% is a palliative doublet platinum-based chemotherapy combined with immunotherapy (if not contraindicated) [5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.